On Monday, Esperion Therapeutics Inc (NASDAQ: ESPR) was 10.06% up from the session before settling in for the closing price of $3.48. A 52-week range for ESPR has been $1.35 – $3.81.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 7.64%. When this article was written, the company’s average yearly earnings per share was at 85.15%. With a float of $195.06 million, this company’s outstanding shares have now reached $195.44 million.
The extent of productivity of a business whose workforce counts for 240 workers is very important to gauge. In terms of profitability, gross margin is 81.57%, operating margin of 5.57%, and the pretax margin is -29.37%.
Esperion Therapeutics Inc (ESPR) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Esperion Therapeutics Inc stocks. The insider ownership of Esperion Therapeutics Inc is 1.00%, while institutional ownership is 65.84%. The most recent insider transaction that took place on Nov 19 ’24, was worth 427. In this transaction Chief Commercial Officer of this company sold 197 shares at a rate of $2.17, taking the stock ownership to the 162,355 shares. Before that another transaction happened on Nov 19 ’24, when Company’s Officer proposed sale 197 for $2.17, making the entire transaction worth $427.
Esperion Therapeutics Inc (ESPR) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 85.15% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 16.90% during the next five years compared to 23.09% growth over the previous five years of trading.
Esperion Therapeutics Inc (NASDAQ: ESPR) Trading Performance Indicators
You can see what Esperion Therapeutics Inc (ESPR) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 1.37. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.66.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.66, a number that is poised to hit -0.14 in the next quarter and is forecasted to reach 0.33 in one year’s time.
Technical Analysis of Esperion Therapeutics Inc (ESPR)
The latest stats from [Esperion Therapeutics Inc, ESPR] show that its last 5-days average volume of 7.07 million was superior to 6.18 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 77.85%. Additionally, its Average True Range was 0.28.
During the past 100 days, Esperion Therapeutics Inc’s (ESPR) raw stochastic average was set at 95.34%, which indicates a significant increase from 93.92% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 87.35% in the past 14 days, which was higher than the 74.91% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.31, while its 200-day Moving Average is $2.24. Now, the first resistance to watch is $4.06. This is followed by the second major resistance level at $4.30. The third major resistance level sits at $4.65. If the price goes on to break the first support level at $3.47, it is likely to go to the next support level at $3.12. The third support level lies at $2.88 if the price breaches the second support level.
Esperion Therapeutics Inc (NASDAQ: ESPR) Key Stats
There are 197,035K outstanding shares of the company, which has a market capitalization of 786.27 million. As of now, sales total 116,330 K while income totals -209,250 K. Its latest quarter income was 51,630 K while its last quarter net income were -29,520 K.
